Pfizer Q2 2025 revenue $14.7B (+10% YoY); raises FY adjusted EPS guidance to $2.90-$3.10

PFIZER INC

2025-Q2 EPS reported $1.03 revenue$28,367,000,000

Reported diluted EPS $0.51; adjusted diluted EPS $0.78, up 30% YoY.
FY 2025 revenue guidance reaffirmed at $61B-$64B; adjusted EPS guidance raised by $0.10 to $2.90-$3.10.
Vyndaqel family revenue up 21% operationally; Comirnaty +95%; Paxlovid +71%; Padcev +38%; Eliquis +6%.
Completed $1.25B upfront in-licensing of 3SBio's SSGJ-707; one-time ~$0.20 EPS impact in Q3.
On track for $7.2B net cost savings by end of 2027; capital allocation includes $4.9B dividends in H1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.